RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 190 filers reported holding RECURSION PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 1.13 and the average weighting 0.9%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2023 | $72,333 | +28.9% | 7,336 | 0.0% | 0.01% | +20.0% |
Q3 2023 | $56,120 | +36.5% | 7,336 | +33.3% | 0.01% | +66.7% |
Q2 2023 | $41,100 | +12.0% | 5,502 | 0.0% | 0.00% | 0.0% |
Q1 2023 | $36,698 | -13.5% | 5,502 | 0.0% | 0.00% | -25.0% |
Q4 2022 | $42,420 | -28.1% | 5,502 | 0.0% | 0.00% | -50.0% |
Q3 2022 | $59,000 | +168.2% | 5,502 | +100.0% | 0.01% | +166.7% |
Q2 2022 | $22,000 | -53.2% | 2,751 | 0.0% | 0.00% | -40.0% |
Q4 2021 | $47,000 | – | 2,751 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Kinnevik AB (publ) | 10,405,668 | $77,730,340 | 100.00% |
Data Collective IV GP, LLC | 5,941,120 | $44,380,166 | 32.86% |
MV Management XI, L.L.C. | 1,971,908 | $14,730,153 | 25.77% |
MIC Capital Management UK LLP | 8,451,758 | $63,134,635 | 12.84% |
Yong Rong (HK) Asset Management Ltd | 1,174,200 | $8,772 | 3.85% |
ArchPoint Investors | 1,114,626 | $8,326,256 | 3.22% |
PLATINUM INVESTMENT MANAGEMENT LTD | 2,711,148 | $20,252,276 | 0.70% |
HARVARD MANAGEMENT CO INC | 882,129 | $6,590 | 0.65% |
Diametric Capital, LP | 119,906 | $895,698 | 0.40% |
Lingotto Investment Management LLP | 775,077 | $5,789,825 | 0.37% |